Document is current
Any future updates will be listed below
-
Authors
Fukui, Michiaki
Tsuboi, Satoshi
Yamamoto, Yuiko https://orcid.org/0000-0003-2673-6238
Terauchi, Yasuo
-
Funding
Funding for this research was provided by:
Novo Nordisk Pharma Ltd
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 5 January 2026
First Online: 27 January 2026
Declarations
:
: This study was conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study was approved by the nonprofit organization MINS institutional review board (approval code number 230208).
: Michiaki Fukui received grants from Abbott Japan, Astellas Pharma, Daiichi Sankyo, Eli Lilly Japan, Johnson & Johnson, Kissei Pharma, Kowa Pharma, Kyowa Kirin, Mitsubishi Tanabe Pharma, MSD, Nippon Chemiphar, Nippon Boehringer Ingelheim, Novo Nordisk Pharma Ltd, Oishi Kenko Inc., Ono Pharma, Sanofi, Sanwa Kagagu Kenkyusho, Sumitomo Dainippon Pharma, Taisho Pharma, Takeda, Tejin Pharma, Terumo Corporation, and Yamada Bee Farm. Satoshi Tsuboi and Yuiko Yamamoto are employees and shareholders of Novo Nordisk Pharma Ltd. Yasuo Terauchi received consulting/lecture fees from Astellas Pharma, AstraZeneca, Eli Lilly Japan, Kowa Company, Mitsubishi Tanabe Pharma, MSD, Nippon Boehringer Ingelheim, Novo Nordisk Pharma Ltd, Sanofi, and Sumitomo Pharma; and grants from Nippon Boehringer Ingelheim and Sumitomo Pharma.
